Last updated: May 26, 2026
Latanoprostene bunod (LBN), marketed in the US as VYZULTA ophthalmic solution, is sourced through a tightly controlled small-molecule supply chain centered on ophthalmic sterile manufacturing. Key supply dependencies cluster around (1) API manufacture for the latanoprostene bunod active, (2) formulation and sterile filling of the ophthalmic drops, and (3) specialized packaging for ocular delivery. Identifying the exact supplier set requires Orange Book-linked labeling supply chains, FDA facility listings tied to the registered drug product, and company disclosures in regulatory submissions and manufacturing quality agreements.
H1: Latanoprostene Bunod Suppliers and Manufacturing Sources for API and Ophthalmic Drug Product
Who supplies latanoprostene bunod API for VYZULTA?
The API supplier set for latanoprostene bunod is typically limited to a small number of qualified chemical manufacturers with demonstrated control over stereochemistry, purity specifications, and scale for ophthalmic-grade material. In practice, API supply is often tied to the drug sponsor’s registered manufacturing sites in FDA submissions, plus quality agreements that restrict secondary sourcing for a sterile ophthalmic product.
What to look for in FDA manufacturing listings for the API
- Registered API-manufacturing facilities tied to the approved NDA/BLA.
- Facility identifiers that map to later inspection history and CMC changes.
- Evidence of commercial supply continuity (site use across batches and supplements).
How API sourcing affects cost and supply risk
- Limited qualified sites for complex synthesis drives higher switching friction.
- Any API site change typically triggers CMC supplement work and can impact shelf life continuity.
Which companies manufacture the latanoprostene bunod ophthalmic solution (sterile filling)?
For VYZULTA, the bottleneck is usually sterile drug-product manufacturing: formulation, sterilization strategy validation, sterile filtration or aseptic processing, and ophthalmic-grade packaging integrity assurance. This is where supply chain concentration is most visible to procurement teams, since sterile manufacturing is facility-specific and tightly regulated.
Key drug-product supply roles in ophthalmic drops
- Formulation and sterile processing
- Aseptic filling into the final dropper container
- Packaging assembly for ocular delivery (compatibility with bottle material, closure integrity)
- Batch-release testing and stability program management
Why ophthalmic sterile supply is concentrated
- Sterile processing lines are dedicated by product family risk assessments.
- Changeovers require validation and comparability packages that discourage multi-sourcing.
What Orange Book listings identify the manufacturing and exclusivity holders for latanoprostene bunod?
For suppliers, the Orange Book record is most useful as a map between:
- The approved label claim for the specific drug product strength/dosage form
- The application holder (market authorization holder)
- The approved product’s relevant patent estate that can indirectly signal which sponsor owns the CMC and manufacturing platform
Practical procurement linkage
- Orange Book lists the approved formulation and associated patents but does not always enumerate contract manufacturers by name.
- For supplier identification, Orange Book must be cross-referenced to FDA drug facility registrations and the facility details included in the drug’s labeling and CMC sections.
Which FDA-registered facilities supply VYZULTA to US patients?
US commercial supply is routed through FDA-registered establishments that perform manufacturing steps such as:
- Preparation, packaging, and labeling
- Sterile drug-product manufacturing and filling
- Quality control release testing
How to translate facility registrations into a supplier shortlist
- Identify facilities associated with the VYZULTA application and supplements.
- Match those facilities to company names via the FDA establishment registry and corporate ownership.
- Confirm which site performs sterile filling vs. secondary packaging to prevent procurement errors.
What contract manufacturers typically compete for ophthalmic sterile filling for latanoprostene bunod?
Ophthalmic sterile filling is dominated by large contract development and manufacturing organizations (CDMOs) with:
- Aseptic processing and sterile filtration capabilities for ophthalmic solutions
- Expertise in low-dose, preservative-containing ocular formulations
- Controlled change management for batch comparability
Typical CDMO capability requirements
- Ophthalmic container-closure system compatibility testing
- Container-closure integrity verification
- Stability-indicating assays for API and impurities
- Sterile assurance controls and environmental monitoring programs
How do supplier changes affect VYZULTA supply continuity and batch release?
Supplier transitions are constrained by the sterile ophthalmic environment:
- CMC changes (process, site, equipment) require comparability and bridging data
- Validation downtime and stability pulls can create lead time increases
- Batch release delays can arise when bridging is not fully streamlined
Common operational choke points
- Sterile filling line availability
- Container-closure system supply continuity
- Release testing capacity for ophthalmic-grade microbial and chemical endpoints
What manufacturing and IP constraints limit alternative suppliers for latanoprostene bunod?
Even when additional manufacturing capacity exists, alternative suppliers can be constrained by:
- Proprietary formulation/process controls tied to the sponsor’s know-how
- Patent-protected methods of manufacture or formulation strategies (when present in the estate)
- Submission ownership and data exclusivity frameworks that impact change execution velocity
Why procurement should separate “possible” from “qualified”
- “Qualified” means validated with the sponsor’s acceptance criteria and regulatory expectations
- Many facilities can perform sterile filling but cannot meet sponsor-specific release specs and stability commitments on a short timeline
Key supplier intelligence checklist for latanoprostene bunod procurement
Procurement teams can build a usable supplier shortlist with a structured approach:
- Drug-product manufacturer: locate FDA-registered sterile filling/packaging sites tied to VYZULTA.
- API manufacturer: locate registered API-manufacturing sites tied to the application.
- Release testing: identify QC testing facilities and responsibilities split.
- Stability program: map which site holds stability protocol execution and trending.
- Container-closure supplier: identify OEM sources if the closure system is custom or tightly specified.
- Regulatory change history: track CMC supplement frequency to gauge site stability.
Key Takeaways
- Latanoprostene bunod supply for VYZULTA is concentrated around qualified sterile ophthalmic manufacturing and controlled API production.
- The most reliable supplier identification comes from FDA establishment registrations mapped to the VYZULTA application, with Orange Book used to anchor the approved product and sponsor linkage.
- Supplier substitutions carry high friction due to sterile processing validation, container-closure compatibility, and batch-release testing demands.
FAQs
-
How do I identify the contract manufacturer for VYZULTA sterile filling?
Use FDA establishment registrations tied to the VYZULTA application and map facilities that perform sterile drug-product manufacturing and packaging.
-
Can multiple API suppliers support latanoprostene bunod without CMC supplements?
Usually not. API site changes typically require CMC comparability and regulatory bridging to support batch release.
-
What contract manufacturing capabilities are required for ophthalmic solutions like VYZULTA?
Aseptic or validated sterilization workflow, ophthalmic container-closure compatibility, stability-indicating assays, and sterile assurance testing.
-
Do Orange Book patents determine who can manufacture latanoprostene bunod?
They can indirectly constrain manufacturing by protecting formulation and methods, but supplier identification still relies on FDA manufacturing listings and regulatory filings.
-
What supply-chain events most often disrupt latanoprostene bunod availability?
Sterile filling line downtime, container-closure supply interruptions, and batch release delays tied to release testing bottlenecks.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drug products.
- U.S. Food and Drug Administration. FDA Establishment Registration and Drug Listing.
